In the past week, GMRE stock has gone down by -3.52%, with a monthly gain of 1.07% and a quarterly surge of 0.35%. The volatility ratio for the week is 1.88%, and the volatility levels for the last 30 days are 2.44% for Global Medical REIT Inc The simple moving average for the past 20 days is -2.78% for GMRE’s stock, with a -3.96% simple moving average for the past 200 days.
Is It Worth Investing in Global Medical REIT Inc (NYSE: GMRE) Right Now?
The price-to-earnings ratio for Global Medical REIT Inc (NYSE: GMRE) is above average at 713.45x. The 36-month beta value for GMRE is also noteworthy at 1.18. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for GMRE is 63.09M, and at present, short sellers hold a 2.13% of that float. The average trading volume of GMRE on March 21, 2025 was 509.94K shares.
GMRE) stock’s latest price update
Global Medical REIT Inc (NYSE: GMRE) has seen a decline in its stock price by -2.30 in relation to its previous close of 8.69. However, the company has experienced a -3.52% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-21 that The current market environment suggests a potential recession, leading investors to favor durable and income-producing assets. BDCs and REITs are likely to be among the key beneficiaries here. However, with REITs and especially BDCs investors have to be careful in order to avoid falling in a value trap.
Analysts’ Opinion of GMRE
Many brokerage firms have already submitted their reports for GMRE stocks, with Berenberg repeating the rating for GMRE by listing it as a “Buy.” The predicted price for GMRE in the upcoming period, according to Berenberg is $11.75 based on the research report published on October 18, 2024 of the previous year 2024.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see GMRE reach a price target of $12. The rating they have provided for GMRE stocks is “Buy” according to the report published on September 19th, 2024.
Robert W. Baird gave a rating of “Neutral” to GMRE, setting the target price at $9 in the report published on October 10th of the previous year.
GMRE Trading at 2.56% from the 50-Day Moving Average
After a stumble in the market that brought GMRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.95% of loss for the given period.
Volatility was left at 2.44%, however, over the last 30 days, the volatility rate increased by 1.88%, as shares surge +1.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.52% upper at present.
During the last 5 trading sessions, GMRE fell by -3.30%, which changed the moving average for the period of 200-days by -8.59% in comparison to the 20-day moving average, which settled at $8.73. In addition, Global Medical REIT Inc saw 9.97% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for GMRE
Current profitability levels for the company are sitting at:
- 0.28 for the present operating margin
- 0.73 for the gross margin
The net margin for Global Medical REIT Inc stands at 0.05. The total capital return value is set at 0.07. Equity return is now at value 1.19, with 0.53 for asset returns.
Based on Global Medical REIT Inc (GMRE), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.11. The debt to equity ratio resting at 1.22. The interest coverage ratio of the stock is 1.4.
Currently, EBITDA for the company is 91.47 million with net debt to EBITDA at 6.6. When we switch over and look at the enterprise to sales, we see a ratio of 8.51. The receivables turnover for the company is 18.57for trailing twelve months and the total asset turnover is 0.11.
Conclusion
In summary, Global Medical REIT Inc (GMRE) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
